# Table S1

| Severity Cohort | non-hospitalized | hospitalized | intubated | deceased | immunosuppressed |
|---|---|---|---|---|---|
| **Total** | n = 18 | n = 45 | n = 27 | n = 10 | n = 13 |
| **Demographics** | | | | | |
| Age (median, range) | 26.5 (0 - 68) | 66 (0 - 91) | 63 (35 - 83) | 60 (39 - 77) | 60 (29 - 80) |
| Sex (% male) | 50% (9/18) | 49% (22/45) | 78% (21/27) | 70% (7/10) | 62% (8/13) |
| Language, primary (% non-English) | 39% (7/18) | 36% (16/45) | 59% (16/27) | 20% (2/10) | 8% (1/13) |
| **Clinical Course** | | | | | |
| PCR-positive days◊ (median, range) | 11 (0 - 44) | 17 (2 - 55) | 34.5 (13 - 68) | 19.5 (7 - 35) | 36 (10 - 55) |
| Hospitalized | 0% (0/18) | 100% (45/45) | 100% (27/27) | 100% (10/10) | 85% (11/13) |
| Days hospitalized (median, range) | - | 5 (1 - 41) | 43 (15 - 118) | 31.5 (1 - 66) | 10 (0 - 50) |
| Intubated | 0% (0/18) | 0% (0/45) | 100% (27/27) | 90% (9/10) | 38% (5/13) |
| Days intubated (median, range) | - | - | 26 (6 - 65) | 22.5 (0 - 57) | 0 (0 - 41) |
| ECMO | 0% (0/18) | 0% (0/45) | 7% (2/27) | 20% (2/10) | 0% (0/13) |
| Deceased | 0% (0/18) | 0% (0/45) | 0% (0/27) | 100% (10/10) | 0% (0/13) |
| **Pre-existing medical conditions** | | | | | |
| No significant conditions | 94% (17/18) | 9% (4/45) | 4% (1/27) | 20% (2/10) | 0% (0/13) |
| Lung disease | 0% (0/18) | 31% (14/45) | 11% (3/27) | 10% (1/10) | 0% (0/13) |
| Heart disease | 0% (0/18) | 36% (16/45) | 11% (3/27) | 20% (2/10) | 15% (2/13) |
| Vascular disease | 0% (0/18) | 13% (6/45) | 0% (0/27) | 10% (1/10) | 0% (0/13) |
| Hypertension | 6% (1/18) | 56% (25/45) | 70% (19/27) | 40% (4/10) | 31% (4/13) |
| Diabetes mellitus | 0% (0/18) | 40% (18/45) | 59% (16/27) | 30% (3/10) | 15% (2/13) |
| Obesity | 0% (0/18) | 22% (10/45) | 37% (10/27) | 0% (0/10) | 8% (1/13) |
| Kidney disease | 0% (0/18) | 22% (10/45) | 11% (3/27) | 10% (1/10) | 38% (5/13) |
| Autoimmune disease | 6% (1/18) | 7% (3/45) | 0% (0/27) | 10% (1/10) | 46% (6/13) |
| Hematologic malignancy | 0% (0/18) | 0% (0/45) | 0% (0/27) | 0% (0/10) | 23% (3/13) |
| Non-hematology malignancy | 0% (0/18) | 11% (5/45) | 7% (2/27) | 20% (2/10) | 0% (0/13) |
| Solid organ transplant | 0% (0/18) | 0% (0/45) | 0% (0/27) | 10% (1/10) | 46% (6/13) |
| HSC transplant | 0% (0/18) | 0% (0/45) | 0% (0/27) | 0% (0/10) | 8% (1/13) |
| Immunosuppressed | 0% (0/18) | 0% (0/45) | 0% (0/27) | 0% (0/10) | 100% (13/13) |
| **Treatments received** | | | | | |
| Hydroxychloroquine | 0% (0/18) | 9% (4/45) | 11% (3/27) | 10% (1/10) | 8% (1/13) |
| Azithromycin | 0% (0/18) | 7% (3/45) | 15% (4/27) | 10% (1/10) | 23% (3/13) |
| Remdesivir | 0% (0/18) | 7% (3/45) | 15% (4/27) | 10% (1/10) | 38% (5/13) |
| Tocilizumab† | 0% (0/18) | 22% (10/45) | 19% (5/27) | 0% (0/10) | 31% (4/13) |
| Anakinra | 0% (0/18) | 0% (0/45) | 4% (1/27) | 0% (0/10) | 0% (0/13) |
| Corticosteroids | 0% (0/18) | 7% (3/45) | 7% (2/27) | 10% (1/10) | 15% (2/13)✵ |

\* PCR-positive days is defined as the numbers of days from the first documents PCR-positive result to the last document PCR-positive result that was followed by at least one PCR-negative result

† The majority of patients receiving tocilizumab were enrolled in a blinded randomized control trial with 2:1 randomization of tocilizumab to placebo, except for two patient who received it off-label

✵ In the immunosuppressed cohort, corticosteroid treatment refers to patients that newly started corticosteroids or had an increase in their baseline dose of corticosteroids (if applicable)

**Table S1. Clinical data from COVID-19 patients, Related to Figure 1.** Clinical data is shown for each pre-defined severity cohort.